Brief: Janone Completes Pre-Ind Meeting With FDA On Jan123
April 18 (Reuters) - Janone Inc JAN.O :
* JANONE COMPLETES PRE-IND MEETING WITH FDA ON JAN123
* JANONE INC: COMPANY NOW HAS PATHWAY TOWARD FORMAL DRUG
APPLICATION FOR JAN123
* JANONE COMPLETES PRE-IND MEETING WITH FDA ON JAN123
* JANONE INC: AGENCY'S FEEDBACK WILL BE USED TO MOVE JAN123
TOWARD
A NEW DRUG APPLICATION UNDER A 505-B2 DESIGNATION
Source text for Eikon: ID:nPn1Zg2c8a
Further company coverage: JAN.O
Recent news on AI Financial
See all newsCorrected: UPDATE 1-Trump-linked fintech firm AI Financial sells unit to PrimeDelta
Trump-linked fintech AI Financial sells unit to Prime Delta
Perpetuals.com ends acquisition talks with Trump-linked crypto firm
Brief: ALT5 Sigma Corporation Restores Compliance With Nasdaq Periodic Filing Requirements
Brief: Alt5 Sigma Expects To File Its Quarterly Report On Form 10-Q